Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’
Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’. // Annals of the Rheumatic Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S0003496726002785?dgcid=rss_sd_all
Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’. Annals of the Rheumatic Diseases. https://www.sciencedirect.com/science/article/pii/S0003496726002785?dgcid=rss_sd_all
“Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’.” Annals of the Rheumatic Diseases.
@article{article35849,
title = {Response to correspondence on ‘Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity (SORAIRO trial)’},
journal = {Annals of the Rheumatic Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S0003496726002785?dgcid=rss_sd_all}
}